Aquestive therapeutics reports positive results from latest clinical studies evaluating pharmacokinetic and pharmacodynamic performance of anaphylm ™ (epinephrine) sublingual film and provides findings from recent auto-injector clinical study

Warren, n.j., may 31, 2023 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (the “company” or “aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today released topline clinical data from recent pilot studies that were completed following the end-of-phase 2 meeting with the fda. the studies included examining (1) differences in pharmacokinetic (pk) results based on changes to administration instructions, (2) additional repeat dose data on anaphylm, and (3) the differences between approved auto-injectors.
AQST Ratings Summary
AQST Quant Ranking